ALKEM · Pharma & Healthcare · mid cap · Midcap 50
What the business sold
What it kept after tax
Profit from operations
Cash the operations produced
Borrowings against the business
Paid out per share · not collected yet
Price index · Start = 100 · Dividends excluded · ₹5,087.5 today (-0.98%)
As of 13 Sept 2026
Price to book 4.4
Trailing twelve months
Closing prices
| Reported metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 11,440 | 12,439 | 12,805 | 14,532 |
| Operating profit | 1,334 | 1,985 | 2,184 | 2,649 |
| Net profit | 984 | 1,796 | 2,165 | 2,302 |
| Operating cash flow | 1,683 | 1,948 | 1,913 | 1,963 |
| Free cash flow | 1,450 | 1,689 | 1,237 | 1,346 |
| Capital expenditure | -233 | -259 | -676 | -617 |
| Tax expense | 298 | 212 | 311 | 518 |
| Total debt | 1,397 | 1,418 | 1,381 | 2,047 |
| Cash and equivalents | 274 | 455 | 304 | 248 |
| Shareholders equity | 9,045 | 10,312 | 11,985 | 13,820 |
| Earnings per share (₹) | 82.31 | 150.19 | 181.11 | 192.51 |
Not collected yet for this company: Dividend per share. These come from the filings, not the daily price feed.
| Quarter ended | Revenue | Operating profit | Net profit | EPS (₹) |
|---|---|---|---|---|
| 30 Jun 2026 | 3,740 | 666 | 520 | 43.49 |
| 31 Mar 2026 | 3,603 | 412 | 236 | 19.77 |
| 31 Dec 2025 | 3,737 | 733 | 636 | 53.19 |
| 30 Sept 2025 | 4,001 | 827 | 765 | 63.99 |
| 30 Jun 2025 | 3,371 | 651 | 664 | 55.56 |
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Somebody's reading of events rather than an event. Worth the argument; not a filing.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
The headline states a business fact and a direction that helps it. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.60. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.
Industry: Drug Manufacturers - Specialty & Generic
Prices, fundamentals and developments last verified 13 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.
Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.
Sign in with Google